**Work      Order #1**

**Dated      November 9, 2007**

| Attachment I | Final                Scope of Work, including the description of Services to be provided                and                timeline |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------|

| Attachment II | Budget                and Payment Terms for the Final Scope of                Work |
|--------------------|------------------------------------------------------------------------------------|

**ACKNOWLEDGED,      ACCEPTED AND AGREED TO:**

**AAIPharma      Inc.**

|      |   |   |
|-----------|--------|--------|
| Signature |   | Date   |
|      |   |   |
|      |   |   |
| Name      |   |   |
|      |   |   |
|      |   |   |
| Title     |   |   |

**YM      Biosciences USA Inc.**

| /s/                  David G.P. Allan |   | [ILLEGIBLE] |
|---------------------------------------|--------|-------------|
| Signature                             |   | Date        |
|                                  |   |        |
| David                  G.P. Allan     |   |        |
| Name                                  |   |        |
|                                  |   |        |
| CHAIR                  & CEO      |   |        |
| Title                                 |   |        |

----

**ATTACHMENT      I to Work Order #1**

**Final      Scope of Work**

**Protocol      No. YMB USA1000/009**

**SCOPE      OF WORK:**

| · | Project                Management (USA)  |   | · | Medical                Monitoring (USA)                           |
|--------|------------------------------------------|--------|--------|-------------------------------------------------------------------|
| · | Clinical                Monitoring (USA) |   | · | Pharmacovigilance                (inc OC AERS set-up/maintenance) |
| · | Data                Management           |   | · | Medical                Writing                                    |
| · | Biostatistics                            |   | · | Clinical                Trial Material Distribution (USA)         |

**STUDY      PARAMETERS:**

| **PARAMETERS:**                                                                                                    |                                                   |
|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Number                of Completed Patients:                                                                            | 44                                                     |
|                                                                                                                    | (30                USA patients)                       |
| Number                of Investigative Sites:                                                                           | [*]                                                    |
|                                                                                                                    | (                [*]                  USA)             |
| Estimated                Number of Total CRF Pages Per Patient:                                                         | 150                                                    |
| Estimated                Number of Unique CRF Pages Per Patient:                                                        | 25                                                     |
| Total                Number of CRF Pages:                                                                               | 6,600                                                  |
| Estimated                Number of Queries:                                                                             | 1,320                                                  |
| Total                Number of Serious Adverse Events:                                                                  | [*]                                                    |
| Total                Number of Face-to-Face Project Meetings(alternating                between AAIPharma and YMB USA): | 4                with PM 2                  with Team  |
| Total                Number of Teleconferences:                                                                         | 47                with PM/RA (24 inc. Team)            |
| **USA                SITES**                                                                                            |                                                   |
| Total                Number of Qualification Site Assessment (QSA)                                                      |                                                   |
| Visits:                                                                                                                 | To                be performed during Initiation Visit |
|                                                                                                                    |                                                   |
| Total                Number of Initiation Visits:                                                                       | 8                                                      |
|                                                                                                                    |                                                   |
| Total                Number of Interim Visits:                                                                          | Average                5 two-day Visits per site       |
|                                                                                                                    |                                                   |
| Total                Number of Closeout Visits:                                                                         | 8                                                      |
|                                                                                                                    |                                                   |
| Total                Number of Tables:                                                                                  | 30                                                     |
| Total                Number of Listings:                                                                                | 25                                                     |
| Total                Number of Figures:                                                                                 | 5                                                      |
| Total                Number of Outputs:                                                                                 | 5                                                      |

| **AAIPharma/YMB                USA Work Order #1 R3** | **Page                1 of 5** |
|-------------------------------------------------------|--------------------------------|
| **Attachment                I**                       |                           |
|                                                  |                           |

----

**TIMELINE**

| **TIME              LINE**                          |                                                                           |
|-----------------------------------------------------|--------------------------------------------------------------------------------|
| Project                Award (LOI executed):        | August                27, 2007                                                 |
| Study                Start-up:                      | 3                months                                                        |
| Patient                Enrollment Duration:         | 14                months                                                       |
| Patient                Treatment Duration:          | Up                to 4.5 months (18 weeks)                                     |
| Follow-up                Duration:                  | Up                to 4 months                                                  |
| Database                Lock:                       | 1                month after last CRF in-house                                 |
| Draft                Tables, Listings and Figures1: | 3                Weeks from Database Lock                                      |
| Final                Tables, Listings and Figures1: | 2                Weeks from Receipt of YMB USA’s                Comments |
| Draft                Report1:                       | 4                Weeks from Final Tables, Listings and Figures                 |
| Final                Report1:                       | 2                Weeks from Receipt of YMB USA’s Comments                |
| **TOTAL                PROJECT DURATION**           | **29                months**                                                   |

**TASK      OWNERSHIP**

**Study      Setup (services to achieve the “First Patient Enrolled”milestone)**

| **Service**                                                          |   | **YMB                USA****Responsibility** |   | **AAIPharma****Responsibility**                            |
|----------------------------------------------------------------------|--------|----------------------------------------------|--------|------------------------------------------------------------|
| Kickoff                Meeting                                       |   | ü                                       |   | ü                                                     |
| Prepare                Project Operational Plan (POP)                |   |                                         |   | ü                                                     |
| CRF                Design                                            |   |                                         |   | ü                                                     |
| CRF                Printing and Shipping                             |   |                                         |   | ü                                                     |
| Develop                Model Informed Consent Form                   |   |                                         |   | ü                                                     |
| Investigator                Selection                                |   | ü                                       |   |                                                       |
| Conduct                Qualifying Site Assessment Visits (USA Sites) |   |                                         |   | Performed                atInitiation                Visit |
| Collect/Review                Regulatory Documents (USA Sites)       |   |                                         |   | ü                                                     |

| **AAIPharma/YMB                USA Work Order #1 R3** | **Page                2 of 5** |
|-------------------------------------------------------|--------------------------------|
| **Attachment                I**                       |                           |

----

| **Service**                                                                                                         |   | **YMB                USA****Responsibility** |   | **AAIPharma****Responsibility** |
|---------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------|--------|---------------------------------|
| Maintain                Trial Master File (USA Sites)                                                               |   |                                         |   | ü                          |
| File                Regulatory Documents with FDA                                                                   |   | ü                                       |   |                            |
| Coordinate                Investigational Product Packaging/Shipping                                                |   | ü                                       |   | US                Sites         |
| ·    Client                  will provide ready-to distribute clinical supplies            |   |                                         |   |                            |
| ·    storage                  at                  2-8C                                     |   |                                         |   |                            |
| ·    Distribution                  performed at 2-8C w/ temperature monitoring required    |   |                                         |   |                            |
| ·    Drug                  return                  activities and destruction not required |   |                                         |   |                            |
| Assist                sites with IRB requirements                                                                   |   |                                         |   | ü                          |
| Negotiate                Site Agreements                                                                            |   | ü                                       |   |                            |
| Execute                Site Agreements                                                                              |   | ü                                       |   |                            |
| Plan                and Coordinate Investigators’ Meeting                                                     |   | ü                                       |   |                            |
| Attend                Investigators’ Meeting                                                                  |   | ü                                       |   | ü                          |
|                                                                                                                |   |                                         |   | 5                attendees      |
| Attend                Training Meeting                                                                              |   | ü                                       |   | ü                          |
| Conduct                Initiation Visits with Medical Monitor                                                       |   |                                         |   | US                Sites         |
| Develop                Monitor Guidelines and Source Document Verification Plan                (SDVP)               |   |                                         |   | ü                          |
| Database                Design                                                                                      |   |                                         |   | ü                          |
| Data                Management Operational Plan (DMOP)                                                              |   |                                         |   | ü                          |
| Generate                Statistical Analysis Plan                                                                   |   |                                         |   | ü                          |

**Ongoing      Study Management (Services from First Patient Enrolled through Database      Lock)**

| **Service**                                                  |   | **YMB                USA****Responsibility** |   | **AAIPharma****Responsibility** |
|--------------------------------------------------------------|--------|----------------------------------------------|--------|---------------------------------|
| Provide                Interim Monitoring Visits (USA Sites) |   |                                         |   | ü                          |
| Provide                Ongoing Site Management Services (USA |   |                                         |   | ü                          |
| Sites)                                                       |   |                                         |   |                            |
| Administer                Payments of Investigator Grants    |   | ü                                       |   |                            |
| Provide                Status Reports to YMB USA             |   | ü                                       |   |                            |
| Provide                Medical Management (USA)              |   |                                         |   | ü                          |
| Set-up                and Maintain Oracle AERS Database      |   |                                         |   | ü                          |
| Provide                SAE Management                        |   |                                         |   | ü                          |
| Preparation                of SAE narratives                 |   |                                         |   | ü                          |

| **AAIPharma/YMB                USA Work Order #1 R3****Attachment                I** | **Page                3 of 5** |
|--------------------------------------------------------------------------------------|--------------------------------|

----

| **Service**                                                  |   | **YMB                USA****Responsibility** |   | **AAIPharma****Responsibility** |
|--------------------------------------------------------------|--------|----------------------------------------------|--------|---------------------------------|
| Filing                of SAE Reports with the FDA            |   | ü                                       |   |                            |
| Participate                in Project Team Meetings          |   | ü                                       |   | ü                          |
| Participate                in Teleconferences                |   | ü                                       |   | ü                          |
| Provide                Quality Assurance Site Audits         |   |                                         |   | ü                          |
| CRF                and Query Scanning, Tracking, and Storage |   |                                         |   | ü                          |
| Data                Entry                                    |   |                                         |   | ü                          |
| Data                Verification                             |   |                                         |   | ü                          |
| Integration                of External Electronic Data       |   |                                         |   | ü                          |
| Data                Validation                               |   |                                         |   | ü                          |
| Data                Coding                                   |   |                                         |   | ü                          |
| SAE                Report Reconciliation against CRF Data    |   |                                         |   | ü                          |
| Database                Quality Control Audit                |   |                                         |   | ü                          |
| Provide                Clean, Locked Database to YMB USA     |   |                                         |   | ü                          |
| Quality                Assurance Site Audits                 |   |                                         |   | ü                          |
|                                                         |   |                                         |   | Optional                        |
| Advance                Planning for Study Report             |   | ü                                       |   | ü                          |

| **AAIPharma/YMB                USA Work Order #1 R3** | **Page                4 of 5** |
|-------------------------------------------------------|--------------------------------|
| **Attachment                I**                       |                           |

----

**Study      Closeout Services (Services from Database Lock to final      Deliverable)**

| **Service**                                                       |   | **YMB                USA****Responsibility** |   | **AAIPharma****Responsibility** |
|-------------------------------------------------------------------|--------|----------------------------------------------|--------|---------------------------------|
| Conduct                Study Closeout Visits (USA Sites)          |   |                                         |   | ü                          |
| Generate                Statistical Tables, Listings, and Figures |   |                                         |   | ü                          |
| Attend                Results Review Meeting                      |   | ü                                       |   | ü                          |
| Generate                Draft Clinical Study Report (CSR)         |   |                                         |   | ü                          |
| Comment                on Draft CSR                               |   | ü                                       |   |                            |
| Finalize                Clinical Study Report                     |   |                                         |   | ü                          |
| Prepare                and Transfer SAS Code                      |   |                                         |   | ü                          |
| Study                Closeout Meeting                             |   | ü                                       |   | ü                          |

| **AAIPharma/YMB                USA Work Order #1 R3****Attachment                I** | **Page                5 of 5** |
|--------------------------------------------------------------------------------------|--------------------------------|

----

**ATTACHMENT      II to Work Order #1**

**Budget      and Payment Terms for the Final Scope of Work**

**ESTIMATED      BUDGET**

**[Intentionally      Left Blank]**

| **AAIPharma/YMB                USA Work Order #1 R2** |   |
|-------------------------------------------------------|--------|
| **Attachment                II**                      |   |

----

| 44    |   | Total                Enrolled Patients |
|-------|--------|----------------------------------------|
| 30    |   | Total                US Patients       |
| 8     |   | US                Sites                |
| 6,600 |   | Total                CRF Pages         |
| 29    |   | Months                Study Duration   |

|                                                                                             |   | **ESTIMATED                BUDGET** |   |
|---------------------------------------------------------------------------------------------|--------|-------------------------------------|--------|
| PROJECT                MANAGEMENT                                                           |   |                                |   |   |   | [*] |   |
| PROJECT                COORDINATION (29 months)                                             |   |                                | [*]    |   |   |  |   |
| PROJECT                MEETINGS AND CONFERENCE CALLS                                        |   |                                | [*]    |   |   |   |   |
|                                                                                        |   |                                |   |   |   |   |   |
| STUDY                SETUP                                                                  |   |                                |   |   |   | [*] |   |
| REGULATORY                DOCUMENT COLLECTION AND PROCESSING                                |   |                                | [*]    |   |   |   |   |
| PROJECT                TEAM TRAINING AND KICK-OFF MEETING                                   |   |                                | [*]    |   |   |   |   |
| INVESTIGATORS                MEETINGS (US Sites Face-to-Face)                               |   |                                |   |   |   |   |   |
| ATTENDANCE                & PARTICIPATION                                               |   |                                | [*]    |   |   |   |   |
| COORDINATION                FEE                                                             |   |                                | [*]    |   |   |   |   |
| CRF                DESIGNS AND INSTRUCTIONS                                                 |   |                                | [*]    |   |   |   |   |
| ADMINISTRATION                & PAYMENT OF LABORATORY                                   |   |                                | [*]    |   |   |   |   |
| ADMINISTRATION                OF INVESTIGATOR GRANTS                                        |   |                                | [*]    |   |   |   |   |
|                                                                                        |   |                                |   |   |   |   |   |
| CLINCAL/MEDICAL                AFFAIRS                                                      |   |                                |   |   |   | [*] |   |
| QSA/INITIATION                VISITS (8)                                                    |   |                                | [*]    |   |   |   |   |
| MEDICAL                MONITOR TO ATTEND QSA/INITIATION VISITS                              |   |                                | [*]    |   |   |   |   |
| INTERIM                MONITORING VISITS (Average 5 two-day visits per site)                |   |                                | [*]    |   |   |   |   |
| CLOSEOUT                VISITS (8)                                                          |   |                                | [*]    |   |   |   |   |
| STATUS                REPORTS                                                               |   |                                | [*]    |   |   |   |   |
| MEDICAL                MANAGEMENT                                                           |   |                                | [*]    |  |   |   |   |
| SAE                MANAGEMENT SET-UP AND MAINTENANCE (Oracle AERS)                          |   |                                | [*]    |   |   |   |   |
| SAE                MANAGEMENT                                                               |   |                                | [*]    |   |   |   |   |
| SAE                NARRATIVES (Includes MedWatch/CIOMS reports)                             |   |                                | [*]    |   |   |   |   |
| SITE                MANAGEMENT                                                              |   |                                | [*]    |   |   |   |   |
| CLINICAL                REGULATORY SITE SUPPORT                                             |   |                                | [*]    |   |   |   |   |
| CLINICAL                PROJECT COORDINATION                                                |   |                                | [*]    |   |   |   |   |
|                                                                                        |   |                                |   |   |   |   |   |
| DATA                MANAGEMENT & CLINICAL DATA SYSTEMS                                  |   |                                |   |   |   | [*] |   |
| DATA                MANAGEMENT OPERATIONAL PLAN                                             |   |                                | [*]    |   |   |   |   |
| DATABASE                DESIGN, PROGRAMMING AND TESTING                                     |   |                                | [*]    |   |   |   |   |
| DATA                ENTRY AND VERIFICATION                                                  |   |                                | [*]    |   |   |   |   |
| DICTIONARY                CODING                                                            |   |                                | [*]    |   |   |   |   |
| CRF                AND QUERY TRACKING & INVENTORY VIA SCANNING                          |   |                                | [*]    |   |   |   |   |
| DATA                VALIDATION INCLUDING QUERY GENERATION & RESOLUTION                  |   |                                | [*]    |   |   |   |   |
| MEDICAL                REVIEW OF CRFs                                                       |   |                                | [*]    |   |   |   |   |
| DATABASE                QUALITY CONTROL AUDIT                                               |   |                                | [*]    |  |   |   |   |
| EXTERNAL                DATA INTEGRATION                                                    |   |                                | [*]    |   |   |   |   |
| DATA                MANAGEMENT PROJECT COORDINATION                                         |   |                                | [*]    |   |   |   |   |
| ADMINISTRATIVE                                                                              |   |                                | [*]    |   |   |   |   |
|                                                                                        |   |                                |   |   |   |   |   |
| BIOSTATISTICAL/REPORT                PREPARATION SERVICES                                   |   |                                |   |   |   | [*] |   |
| STATISTICAL                ANALYSIS PLAN                                                    |   |                                | [*]    |   |   |   |   |
| STATISTICAL                TABLES, LISTINGS & PROGRAMMING                               |   |                                | [*]    |   |   |   |   |
| ANALYSIS                PRODUCTION                                                          |   |                                | [*]    |   |   |   |   |
| INTEGRATED                CLINICAL/STATISTICAL REPORT                                       |   |                                | [*]    |   |   |   |   |
| RESULTS                REVIEW MEETING                                                       |   |                                | [*]    |   |   |   |   |
| BIOSTATISTICAL/REPORT                PROJECT COORDINATION                                   |   |                                | [*]    |   |   |   |   |
|                                                                                        |   |                                |   |   |   |   |   |
| **TOTAL                ESTIMATED BUDGET**                                                   |   |                                | [*]    |   |   |   |   |
|                                                                                        |   |                                |   |   |   |   |   |
| **ADDITIONAL                SERVICES**                                                      |   |                                |   |   |   |   |   |
| **CLINICAL                TRIAL MATERIAL DISTRIBUTION TO US SITES**                         |   |                                | [*]    |   |   |   |   |
|                                                                                        |   |                                |   |   |   |   |   |
| **TOTAL                ESTIMATED BUDGET EXCLUSIVE OF PASS THROUGH                EXPENSES** |   |                                | [*]    |   |   |   |   |
|                                                                                        |   |                                |   |   |   |   |   |
| **ESTIMATED                PASS THROUGH EXPENSES**                                          |   |                                |   |   |   | [*] |   |
| INVESTIGATOR                MEETING (incidentals @$100/attendee)                            |   |                                | [*]    |   |   |   |   |
| MONITOR                TRAVEL                                                               |   |                                | [*]    |   |   |   |   |
| MEDICAL                MONITOR TRAVEL (8 VISITs)                                            |   |                                | [*]    |   |   |   |   |
| CRF                PRINTING AND SHIPPING                                                    |   |                                | [*]    |   |   |   |   |
| PROJECT                MEETING EXPENSES                                                     |   |                                | [*]    |   |   |   |   |
|                                                                                        |   |                                |   |   |   |   |   |
| **TOTAL                ESTIMATED BUDGET**                                                   |   |                                | [*]    |   |   |   |   |
|                                                                                        |   |                                |   |   |   |   |   |
| **OPTIONAL                COSTS**                                                           |   |                                |   |   |   |   |   |
| CLINICAL                INTERIM MONITORING                                                  |   |                                |   |   |   |   |   |
| ADDITIONAL                VISIT PER PATIENT (From 1 to 2 Visits per Patient)                |   |                                | [*]    |   |   |   |   |
| SITE                VISIT TRAVEL                                                            |   |                                | [*]    |   |   |   |   |
| QUALITY                ASSURANCE                                                            |   |                                |   |   |   |   |   |
| INVESTIGATOR                SITE VISITS                                                     |   |                                | [*]    |   |   |   |   |
| SITE                VISIT TRAVEL                                                            |   |                                | [*]    |   |   |   |   |

**AAIPharma/YMB      USA Work Order #1 R2**

**Attachment      II**

----

**Payment      Schedule**

**YM      Biosciences**

**YMB1000/009**

|                                                                                                                    |   | First                Budget |   |
|-------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------|--------|
| **Direct                Costs:**                                                                                        |   | USD                         |   |
|                                                                                                                    |   |                        |   |
| Execution                of WorkOrder                                                                              |   | $                           | [*]    |   |
| Milestones:                                                                                                             |   |                        |   |   |
| Monthly                Maintence Fee (Project Management, Site Management, PVG, QA and Medical                Overview) |   |                        |   |   |
| $[*]month                for [*]                months (Sept-07-Jan-07)                                       |   | $                           | [*]    |   |
| Clinical:                                                                                                               |   |                        |   |   |
| Completion                of Base Documents                                                                             |   | $                           | [*]    |   |
| First                Site Initiated                                                                                     |   | $                           | [*]    |   |
| 100%                Sites Initiated                                                                                     |   | $                           | [*]    |   |
| First                Patient Enrolled                                                                                   |   | $                           | [*]    |   |
| 20%                Monitoring Visits Completed                                                                          |   | $                           | [*]    |   |
| 40%                Monitoring Visits Completed                                                                          |   | $                           | [*]    |   |
| 60%                Monitoring Visits Completed                                                                          |   | $                           | [*]    |   |
| 80%                Monitoring Visits Completed                                                                          |   | $                           | [*]    |   |
| 100%                Monitoring Visits Completed                                                                         |   | $                           | [*]    |   |
| All                Sites Closed-out                                                                                     |   | $                           | [*]    |   |
| Database                Set-Up                                                                                          |   | $                           | [*]    |   |
| 50%                CRFs Completed                                                                                       |   | $                           | [*]    |   |
| 100%                CRFs Completed                                                                                      |   | $                           | [*]    |   |
| Database                Lock                                                                                            |   | $                           | [*]    |   |
| Clinical                Study Report                                                                                    |   | $                           | [*]    |   |
| **Total                Direct Costs**                                                                                   |   | $                           | [*]    |   |

**AAIPharma/YMB      USA Work Order #1 R2**

**Attachment      II**

----